MetaStat, Inc. (MTST)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MetaStat, Inc. (MTST) with AI Score 57/100 (Hold). MetaStat, Inc. is a precision medicine company focused on developing therapeutic and diagnostic solutions for cancer patients, particularly targeting the MENA pathway. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026MetaStat, Inc. (MTST) Healthcare & Pipeline Overview
MetaStat, Inc. is a biotechnology company focused on precision medicine, developing diagnostics and therapeutics targeting the MENA pathway in cancer. With a small team, MetaStat aims to improve cancer diagnosis and treatment through novel drug candidates and companion diagnostic tests, operating within the competitive biotechnology sector.
Investment Thesis
MetaStat, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on the MENA pathway, a key driver of metastasis, offers potential for significant breakthroughs in cancer treatment and diagnostics. However, as a small company with a market capitalization of $0.00 billion and negative profitability (Profit Margin: -13652.5%), MetaStat faces substantial challenges in funding its research and development efforts. The company's success hinges on the successful development and commercialization of its product candidates, including the MENA diagnostic assay and companion diagnostics. Upcoming clinical data and potential partnerships will be critical catalysts. The high beta of 9.69 indicates extreme volatility, reflecting the speculative nature of the investment. Investors should carefully consider the risks associated with early-stage biotechnology companies before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Profit Margin of -13652.5% reflects the company's current lack of profitability due to heavy investment in R&D.
- Gross Margin of 100.0% suggests that the company's products, once commercialized, have the potential for high profitability.
- Beta of 9.69 indicates extremely high volatility compared to the market, reflecting the speculative nature of the stock.
- Focus on the MENA pathway, a critical metastatic pathway in solid tumors, positions the company at the forefront of cancer research.
Competitors & Peers
Strengths
- Proprietary focus on the MENA pathway.
- Development of novel diagnostic assays.
- Expertise in precision medicine for cancer.
- Potential for companion diagnostic partnerships.
Weaknesses
- Limited financial resources.
- Small number of employees.
- Early stage of product development.
- Dependence on successful clinical trials.
Catalysts
- Upcoming: Clinical data release from ongoing preclinical studies of therapeutic candidates targeting the MENA pathway.
- Upcoming: Potential partnerships with pharmaceutical companies for companion diagnostic development.
- Ongoing: Continued development and refinement of the MENA diagnostic assay.
- Ongoing: Exploration of new therapeutic applications for the MetaSite Breast assay.
Risks
- Potential: Failure to obtain regulatory approval for diagnostic assays and therapeutic candidates.
- Potential: Competition from larger biotechnology and pharmaceutical companies.
- Potential: Limited financial resources to fund ongoing research and development.
- Ongoing: High volatility associated with OTC-traded stocks.
- Ongoing: Dependence on successful clinical trials and commercialization efforts.
Growth Opportunities
- MENA Diagnostic Assay Commercialization: MetaStat's MENA diagnostic assay, a tissue-based test, has the potential to significantly improve cancer diagnosis and treatment selection. The market for cancer diagnostics is projected to reach $25 billion by 2028, driven by the increasing demand for personalized medicine. Successful commercialization of this assay, potentially within the next 2-3 years, could generate substantial revenue for MetaStat, especially if it becomes a standard of care for certain cancer types.
- Companion Diagnostic Development: MetaStat is developing companion diagnostics to predict responses to RTK inhibitor drugs and anti-microtubule drugs. The market for companion diagnostics is growing rapidly, driven by the increasing use of targeted therapies in cancer treatment. Partnering with pharmaceutical companies to develop and commercialize these diagnostics could provide MetaStat with a significant revenue stream and enhance its credibility in the industry. This could materialize within the next 3-5 years.
- Liquid Biopsy Technology: MetaStat's development of a liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care represents a significant growth opportunity. The liquid biopsy market is expected to reach $10 billion by 2027, driven by its non-invasive nature and potential for early cancer detection. Successful development and commercialization of this technology could position MetaStat as a leader in the field, potentially within the next 4-6 years.
- MetaSite Breast Assay Expansion: The MetaSite Breast assay, an immunohistochemistry test, offers another avenue for growth. By expanding the clinical applications of this assay and securing partnerships with diagnostic laboratories, MetaStat can increase its market reach and revenue. The breast cancer diagnostics market is substantial, and a successful assay could contribute significantly to MetaStat's growth, potentially within the next 2-4 years.
- Therapeutic Development Targeting MENA Pathway: MetaStat's therapeutic program targeting the MENA pathway represents a long-term growth opportunity. While still in early stages, successful development of a drug that inhibits the MENA pathway could revolutionize cancer treatment. The market for cancer therapeutics is enormous, and a successful drug could generate billions of dollars in revenue. However, this is a high-risk, high-reward endeavor with a timeline of 5-10 years.
Opportunities
- Growing market for cancer diagnostics and therapeutics.
- Increasing demand for personalized medicine.
- Potential for partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Threats
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Patent challenges and intellectual property disputes.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary technology targeting the MENA pathway.
- Expertise in developing cancer diagnostics and therapeutics.
- Potential for intellectual property protection through patents.
About MTST
MetaStat, Inc., based in Boston, Massachusetts, is a precision medicine company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for cancer patients. The company's primary focus is on targeting the MENA pathway, a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat is developing a range of product candidates, including the MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures the expression of the pro-metastatic MENA protein splice-variant. This assay is intended to predict responses to RTK inhibitor drugs and anti-microtubule drugs. Additionally, MetaStat is working on a liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care, as well as the MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment. The company also aims to develop a prognostic diagnostic to predict the risk of cancer metastasis. MetaStat's therapeutic approach targets this critical metastatic pathway in solid tumors, aiming to overcome tumor resistance and prevent the spread of aggressive cancer.
What They Do
- Develop diagnostic assays for cancer.
- Create companion diagnostics to predict drug responses.
- Develop liquid blood-based biopsies for cancer diagnosis.
- Research therapeutic targets in the MENA pathway.
- Focus on precision medicine for cancer treatment.
- Develop immunohistochemistry tests for cancer analysis.
Business Model
- Develop and commercialize diagnostic assays for cancer.
- Partner with pharmaceutical companies to develop companion diagnostics.
- Generate revenue through sales of diagnostic products and services.
Industry Context
MetaStat, Inc. operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory hurdles. The company focuses on precision medicine, a growing trend in cancer treatment that aims to tailor therapies to individual patients based on their genetic and molecular profiles. The market for cancer diagnostics and therapeutics is substantial and growing, driven by an aging population and increasing incidence of cancer. MetaStat competes with other biotechnology companies, such as ATRX, CDXI, ELOX, LGBI, and MODC, as well as larger pharmaceutical companies that are also developing cancer treatments. The company's success depends on its ability to develop and commercialize innovative products that address unmet needs in cancer care.
Key Customers
- Hospitals and cancer centers.
- Diagnostic laboratories.
- Pharmaceutical companies.
Financials
Chart & Info
MetaStat, Inc. (MTST) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 30, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MTST.
Price Targets
Wall Street price target analysis for MTST.
MoonshotScore
What does this score mean?
The MoonshotScore rates MTST's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Frederick E. Pierce
CEO
Frederick E. Pierce serves as the CEO of MetaStat, Inc., leading a team of six employees. His background includes extensive experience in the biotechnology and pharmaceutical industries. Pierce has held various leadership positions in companies focused on developing and commercializing innovative therapies. His expertise spans areas such as drug development, clinical trials, and regulatory affairs. Pierce's educational background includes advanced degrees in science and business, providing him with a strong foundation for leading a precision medicine company.
Track Record: Under Frederick E. Pierce's leadership, MetaStat, Inc. has focused on advancing its pipeline of diagnostic assays and therapeutic candidates targeting the MENA pathway. Key milestones include the development of the MENA diagnostic assay and the initiation of preclinical studies for novel drug candidates. Pierce has also been instrumental in securing funding and establishing partnerships to support the company's research and development efforts.
MTST OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MetaStat, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business plan and market opportunity.
- Evaluate the company's intellectual property and competitive landscape.
- Review the company's capitalization structure and ownership.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC securities.
- Company is focused on precision medicine for cancer treatment.
- Development of novel diagnostic assays and therapeutic candidates.
- CEO with experience in the biotechnology industry.
- Company based in Boston, a hub for biotechnology innovation.
Common Questions About MTST
What does MetaStat, Inc. do?
MetaStat, Inc. is a precision medicine company focused on developing and commercializing diagnostic and therapeutic solutions for cancer patients. The company's primary focus is on the MENA pathway, a critical driver of metastasis in solid tumors. MetaStat is developing diagnostic assays, including the MENA diagnostic assay and MetaSite Breast assay, to improve cancer diagnosis and predict treatment responses. Additionally, the company is researching therapeutic candidates that target the MENA pathway to prevent tumor resistance and the spread of aggressive cancer. MetaStat aims to provide personalized cancer care through its innovative products and services.
What do analysts say about MTST stock?
As of March 17, 2026, there is no readily available analyst coverage for MetaStat, Inc. (MTST) due to its OTC listing and small market capitalization. The company's financial performance is characterized by a negative profit margin (-13652.5%) and a high beta (9.69), indicating significant risk and volatility. Investors should conduct their own thorough due diligence and consider the risks associated with investing in early-stage biotechnology companies before making any investment decisions. The company's success depends on the successful development and commercialization of its product candidates.
What are the main risks for MTST?
MetaStat, Inc. faces several significant risks, including the inherent challenges of developing and commercializing new diagnostic and therapeutic products in the biotechnology industry. The company's limited financial resources and small team size pose a risk to its ability to fund ongoing research and development efforts. Clinical trial failures, regulatory hurdles, and competition from larger companies are also potential risks. Additionally, as an OTC-traded stock, MTST is subject to higher volatility and liquidity risks compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing in MetaStat, Inc.
What are the key factors to evaluate for MTST?
MetaStat, Inc. (MTST) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary focus on the MENA pathway.. Primary risk to monitor: Potential: Failure to obtain regulatory approval for diagnostic assays and therapeutic candidates.. This is not financial advice.
How frequently does MTST data refresh on this page?
MTST prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MTST's recent stock price performance?
Recent price movement in MetaStat, Inc. (MTST) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary focus on the MENA pathway.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MTST overvalued or undervalued right now?
Determining whether MetaStat, Inc. (MTST) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MTST?
Before investing in MetaStat, Inc. (MTST), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide additional insights.